LSL Pharma Group Inc.
LSL.V
TSX
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Net Income | -283.00K | -377.10K | -207.70K | -349.80K | -568.10K |
Total Depreciation and Amortization | 259.50K | 252.90K | 247.70K | 179.60K | 258.70K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 345.30K | 567.10K | 340.40K | -190.40K | 318.30K |
Change in Net Operating Assets | -385.70K | -521.10K | -1.80M | -348.30K | -1.82M |
Cash from Operations | -63.80K | -78.20K | -1.42M | -708.90K | -1.81M |
Capital Expenditure | -876.90K | -678.90K | -402.80K | 627.80K | -138.70K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -22.00K | -1.54M | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -122.40K | -148.40K | -108.30K | -145.10K | -18.60K |
Cash from Investing | -1.02M | -2.37M | -511.00K | 482.70K | -157.30K |
Total Debt Issued | 1.76M | 438.00K | 1.26M | 81.20K | 2.94M |
Total Debt Repaid | -957.00K | -1.17M | -440.00K | 926.60K | -165.00K |
Issuance of Common Stock | 960.00K | 5.29M | 1.99M | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -100.00 | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -403.00K | -889.00K | -245.00K | -663.30K | -680.00K |
Cash from Financing | 993.50K | 2.68M | 1.90M | 253.20K | 1.56M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -91.60K | 235.30K | -30.40K | 26.90K | -406.30K |